Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 349 to 357 of 357 entries
Sorted by: Best Match Show Resources per page
Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles.

Frontiers in aging neuroscience

Utz J, Berner J, Muñoz LE, Oberstein TJ, Kornhuber J, Herrmann M, Maler JM, Spitzer P.
PMID: 34295239
Front Aging Neurosci. 2021 Jul 06;13:682115. doi: 10.3389/fnagi.2021.682115. eCollection 2021.

INTRODUCTION: In Alzheimer's disease, the severity of symptoms is linked to a loss of synaptic density and the spread of pathologically hyperphosphorylated tau. The established cerebrospinal fluid markers Aβ, tau and phospho-tau reflect the histopathological hallmarks of Alzheimer's disease...

Cite
Utz J, Berner J, Muñoz LE, et al. Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles. Front Aging Neurosci. 2021;13:682115doi: 10.3389/fnagi.2021.682115.
Utz, J., Berner, J., Muñoz, L. E., Oberstein, T. J., Kornhuber, J., Herrmann, M., Maler, J. M., & Spitzer, P. (2021). Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles. Frontiers in aging neuroscience, 13682115. https://doi.org/10.3389/fnagi.2021.682115
Utz, Janine, et al. "Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles." Frontiers in aging neuroscience vol. 13 (2021): 682115. doi: https://doi.org/10.3389/fnagi.2021.682115
Utz J, Berner J, Muñoz LE, Oberstein TJ, Kornhuber J, Herrmann M, Maler JM, Spitzer P. Cerebrospinal Fluid of Patients With Alzheimer's Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles. Front Aging Neurosci. 2021 Jul 06;13:682115. doi: 10.3389/fnagi.2021.682115. eCollection 2021. PMID: 34295239; PMCID: PMC8290128.
Copy Download .nbib Format: NLM
Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.

Future oncology (London, England)

Díaz LP, Millán S, Chaban N, Campo AD, Spitzer E.
PMID: 33904318
Future Oncol. 2021 Jul;17(19):2529-2544. doi: 10.2217/fon-2020-0923. Epub 2021 Apr 27.

Monoclonal antibodies are highly complex, large and biologic products with a substantial impact on the clinical management of a variety of diseases including cancer. The expiry of patents for essential monoclonal antibodies in cancer care such as bevacizumab, rituximab...

Cite
Díaz LP, Millán S, Chaban N, et al. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncol. 2021;17(19):2529-2544doi: 10.2217/fon-2020-0923.
Díaz, L. P., Millán, S., Chaban, N., Campo, A. D., & Spitzer, E. (2021). Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future oncology (London, England), 17(19), 2529-2544. https://doi.org/10.2217/fon-2020-0923
Díaz, Luis Pérez, et al. "Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars." Future oncology (London, England) vol. 17,19 (2021): 2529-2544. doi: https://doi.org/10.2217/fon-2020-0923
Díaz LP, Millán S, Chaban N, Campo AD, Spitzer E. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. Future Oncol. 2021 Jul;17(19):2529-2544. doi: 10.2217/fon-2020-0923. Epub 2021 Apr 27. PMID: 33904318.
Copy Download .nbib Format: NLM
Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes.

Cell

Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, Schwartz S, Bano D, Latz E, Melki R, Heneka MT.
PMID: 34555357
Cell. 2021 Sep 30;184(20):5089-5106.e21. doi: 10.1016/j.cell.2021.09.007. Epub 2021 Sep 22.

Microglia are the CNS resident immune cells that react to misfolded proteins through pattern recognition receptor ligation and activation of inflammatory pathways. Here, we studied how microglia handle and cope with α-synuclein (α-syn) fibrils and their clearance. We found...

Cite
Scheiblich H, Dansokho C, Mercan D, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184(20):5089-5106.e21doi: 10.1016/j.cell.2021.09.007.
Scheiblich, H., Dansokho, C., Mercan, D., Schmidt, S. V., Bousset, L., Wischhof, L., Eikens, F., Odainic, A., Spitzer, J., Griep, A., Schwartz, S., Bano, D., Latz, E., Melki, R., & Heneka, M. T. (2021). Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell, 184(20), 5089-5106.e21. https://doi.org/10.1016/j.cell.2021.09.007
Scheiblich, Hannah, et al. "Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes." Cell vol. 184,20 (2021): 5089-5106.e21. doi: https://doi.org/10.1016/j.cell.2021.09.007
Scheiblich H, Dansokho C, Mercan D, Schmidt SV, Bousset L, Wischhof L, Eikens F, Odainic A, Spitzer J, Griep A, Schwartz S, Bano D, Latz E, Melki R, Heneka MT. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021 Sep 30;184(20):5089-5106.e21. doi: 10.1016/j.cell.2021.09.007. Epub 2021 Sep 22. PMID: 34555357; PMCID: PMC8527836.
Copy Download .nbib Format: NLM
Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM.

BJPsych open

Heilbronner U, Streit F, Vogl T, Senner F, Schaupp SK, Reich-Erkelenz D, Papiol S, Kohshour MO, Klöhn-Saghatolislam F, Kalman JL, Heilbronner M, Gade K, Comes AL, Budde M, Andlauer TFM, Anderson-Schmidt H, Adorjan K, Stürmer T, Loerbroks A, Amelang M, Poisel E, Foo J, Heilmann-Heimbach S, Forstner AJ, Degenhardt F, Zimmermann J, Wiltfang J, von Hagen M, Spitzer C, Schmauss M, Reininghaus E, Reimer J, Konrad C, Juckel G, Lang FU, Jäger M, Figge C, Fallgatter AJ, Dietrich DE, Dannlowski U, Baune BT, Arolt V, Anghelescu IG, Nöthen MM, Witt SH, Andreassen OA, Chen CH, Falkai P, Rietschel M, Schulze TG, Schulte EC.
PMID: 34789355
BJPsych Open. 2021 Nov 18;7(6):e206. doi: 10.1192/bjo.2021.1037.

No abstract available.

Cite
Heilbronner U, Streit F, Vogl T, et al. Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM. BJPsych Open. 2021;7(6):e206doi: 10.1192/bjo.2021.1037.
Heilbronner, U., Streit, F., Vogl, T., Senner, F., Schaupp, S. K., Reich-Erkelenz, D., Papiol, S., Kohshour, M. O., Klöhn-Saghatolislam, F., Kalman, J. L., Heilbronner, M., Gade, K., Comes, A. L., Budde, M., Andlauer, T. F. M., Anderson-Schmidt, H., Adorjan, K., Stürmer, T., Loerbroks, A., Amelang, M., Poisel, E., Foo, J., Heilmann-Heimbach, S., Forstner, A. J., Degenhardt, F., Zimmermann, J., Wiltfang, J., von Hagen, M., Spitzer, C., Schmauss, M., Reininghaus, E., Reimer, J., Konrad, C., Juckel, G., Lang, F. U., Jäger, M., Figge, C., Fallgatter, A. J., Dietrich, D. E., Dannlowski, U., Baune, B. T., Arolt, V., Anghelescu, I. G., Nöthen, M. M., Witt, S. H., Andreassen, O. A., Chen, C. H., Falkai, P., Rietschel, M., Schulze, T. G., & Schulte, E. C. (2021). Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM. BJPsych open, 7(6), e206. https://doi.org/10.1192/bjo.2021.1037
Heilbronner, Urs, et al. "Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM." BJPsych open vol. 7,6 (2021): e206. doi: https://doi.org/10.1192/bjo.2021.1037
Heilbronner U, Streit F, Vogl T, Senner F, Schaupp SK, Reich-Erkelenz D, Papiol S, Kohshour MO, Klöhn-Saghatolislam F, Kalman JL, Heilbronner M, Gade K, Comes AL, Budde M, Andlauer TFM, Anderson-Schmidt H, Adorjan K, Stürmer T, Loerbroks A, Amelang M, Poisel E, Foo J, Heilmann-Heimbach S, Forstner AJ, Degenhardt F, Zimmermann J, Wiltfang J, von Hagen M, Spitzer C, Schmauss M, Reininghaus E, Reimer J, Konrad C, Juckel G, Lang FU, Jäger M, Figge C, Fallgatter AJ, Dietrich DE, Dannlowski U, Baune BT, Arolt V, Anghelescu IG, Nöthen MM, Witt SH, Andreassen OA, Chen CH, Falkai P, Rietschel M, Schulze TG, Schulte EC. Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection - ADDENDUM. BJPsych Open. 2021 Nov 18;7(6):e206. doi: 10.1192/bjo.2021.1037. PMID: 34789355; PMCID: PMC8632373.
Copy Download .nbib Format: NLM
Are we ready for a name change for schizophrenia? A survey of multiple stakeholders.

Schizophrenia research

Mesholam-Gately RI, Varca N, Spitzer C, Parrish EM, Hogan V, Behnke SH, Larson L, Rosa-Baez C, Schwirian N, Stromeyer C, Williams MJ, Saks ER, Keshavan MS.
PMID: 34688117
Schizophr Res. 2021 Dec;238:152-160. doi: 10.1016/j.schres.2021.08.034. Epub 2021 Oct 20.

About one in 100 people worldwide are diagnosed with schizophrenia. Many people advocate for a name change for the condition, pointing to the stigma and discrimination associated with the term "schizophrenia", as well as to how the name poorly...

Cite
Mesholam-Gately RI, Varca N, Spitzer C, et al. Are we ready for a name change for schizophrenia? A survey of multiple stakeholders. Schizophr Res. 2021;238:152-160doi: 10.1016/j.schres.2021.08.034.
Mesholam-Gately, R. I., Varca, N., Spitzer, C., Parrish, E. M., Hogan, V., Behnke, S. H., Larson, L., Rosa-Baez, C., Schwirian, N., Stromeyer, C., Williams, M. J., Saks, E. R., & Keshavan, M. S. (2021). Are we ready for a name change for schizophrenia? A survey of multiple stakeholders. Schizophrenia research, 238152-160. https://doi.org/10.1016/j.schres.2021.08.034
Mesholam-Gately, Raquelle I, et al. "Are we ready for a name change for schizophrenia? A survey of multiple stakeholders." Schizophrenia research vol. 238 (2021): 152-160. doi: https://doi.org/10.1016/j.schres.2021.08.034
Mesholam-Gately RI, Varca N, Spitzer C, Parrish EM, Hogan V, Behnke SH, Larson L, Rosa-Baez C, Schwirian N, Stromeyer C, Williams MJ, Saks ER, Keshavan MS. Are we ready for a name change for schizophrenia? A survey of multiple stakeholders. Schizophr Res. 2021 Dec;238:152-160. doi: 10.1016/j.schres.2021.08.034. Epub 2021 Oct 20. PMID: 34688117.
Copy Download .nbib Format: NLM
Allergy-induced systemic inflammation impairs tendon quality.

EBioMedicine

Lehner C, Spitzer G, Langthaler P, Jakubecova D, Klein B, Weissenbacher N, Wagner A, Gehwolf R, Trinka E, Iglseder B, Paulweber B, Aigner L, Couillard-Després S, Weiss R, Tempfer H, Traweger A.
PMID: 35007819
EBioMedicine. 2022 Jan 07;75:103778. doi: 10.1016/j.ebiom.2021.103778. Epub 2022 Jan 07.

BACKGROUND: Treatment of degenerating tendons still presents a major challenge, since the aetiology of tendinopathies remains poorly understood. Besides mechanical overuse, further known predisposing factors include rheumatoid arthritis, diabetes, obesity or smoking all of which combine with a systemic...

Cite
Lehner C, Spitzer G, Langthaler P, et al. Allergy-induced systemic inflammation impairs tendon quality. EBioMedicine. 2022;75:103778doi: 10.1016/j.ebiom.2021.103778.
Lehner, C., Spitzer, G., Langthaler, P., Jakubecova, D., Klein, B., Weissenbacher, N., Wagner, A., Gehwolf, R., Trinka, E., Iglseder, B., Paulweber, B., Aigner, L., Couillard-Després, S., Weiss, R., Tempfer, H., & Traweger, A. (2022). Allergy-induced systemic inflammation impairs tendon quality. EBioMedicine, 75103778. https://doi.org/10.1016/j.ebiom.2021.103778
Lehner, Christine, et al. "Allergy-induced systemic inflammation impairs tendon quality." EBioMedicine vol. 75 (2022): 103778. doi: https://doi.org/10.1016/j.ebiom.2021.103778
Lehner C, Spitzer G, Langthaler P, Jakubecova D, Klein B, Weissenbacher N, Wagner A, Gehwolf R, Trinka E, Iglseder B, Paulweber B, Aigner L, Couillard-Després S, Weiss R, Tempfer H, Traweger A. Allergy-induced systemic inflammation impairs tendon quality. EBioMedicine. 2022 Jan 07;75:103778. doi: 10.1016/j.ebiom.2021.103778. Epub 2022 Jan 07. PMID: 35007819; PMCID: PMC8749446.
Copy Download .nbib Format: NLM
Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Stemplewitz B, Luethy J, Eddy MT, Spitzer M, Brocks U, Kieckhoefel J, Schneemann C, Schaudig U, Schargus M.
PMID: 35006330
Graefes Arch Clin Exp Ophthalmol. 2022 Jan 10; doi: 10.1007/s00417-021-05521-5. Epub 2022 Jan 10.

PURPOSE: This study aims to evaluate the impact of the first coronavirus 2019 (COVID-19) wave in 2020 on patients scheduled for intravitreal injections (IVI) in a German metropolitan region.METHODS: We performed a multicentre prospective survey and retrospective analysis of...

Cite
Stemplewitz B, Luethy J, Eddy MT, et al. Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region. Graefes Arch Clin Exp Ophthalmol. 2022;doi: 10.1007/s00417-021-05521-5.
Stemplewitz, B., Luethy, J., Eddy, M. T., Spitzer, M., Brocks, U., Kieckhoefel, J., Schneemann, C., Schaudig, U., & Schargus, M. (2022). Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, . https://doi.org/10.1007/s00417-021-05521-5
Stemplewitz, Birthe, et al. "Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region." Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie vol. (2022). doi: https://doi.org/10.1007/s00417-021-05521-5
Stemplewitz B, Luethy J, Eddy MT, Spitzer M, Brocks U, Kieckhoefel J, Schneemann C, Schaudig U, Schargus M. Impact of the COVID-19 pandemic's first wave on the care and treatment situation of intravitreal injections in a German metropolitan region. Graefes Arch Clin Exp Ophthalmol. 2022 Jan 10; doi: 10.1007/s00417-021-05521-5. Epub 2022 Jan 10. PMID: 35006330.
Copy Download .nbib Format: NLM
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.

European heart journal

Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S, Gonzalo N, Jan van Geuns R, Onuma Y, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Piek JJ, Appleby C, Fath-Ordoubadi F, Zaman A, Van Mieghem NM, Uren N, Zueco J, Buszman P, Iniguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, de Vries T, Taggart D, Farooq V, Spitzer E, Tijssen J, Escaned J.
PMID: 34617993
Eur Heart J. 2021 Oct 07; doi: 10.1093/eurheartj/ehab703. Epub 2021 Oct 07.

AIMS: The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II,...

Cite
Banning AP, Serruys P, De Maria GL, et al. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. Eur Heart J. 2021;doi: 10.1093/eurheartj/ehab703.
Banning, A. P., Serruys, P., De Maria, G. L., Ryan, N., Walsh, S., Gonzalo, N., Jan van Geuns, R., Onuma, Y., Sabate, M., Davies, J., Lesiak, M., Moreno, R., Cruz-Gonzalez, I., Hoole, S. P., Piek, J. J., Appleby, C., Fath-Ordoubadi, F., Zaman, A., Van Mieghem, N. M., Uren, N., Zueco, J., Buszman, P., Iniguez, A., Goicolea, J., Hildick-Smith, D., Ochala, A., Dudek, D., de Vries, T., Taggart, D., Farooq, V., Spitzer, E., Tijssen, J., & Escaned, J. (2021). Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. European heart journal, . https://doi.org/10.1093/eurheartj/ehab703
Banning, Adrian P, et al. "Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study." European heart journal vol. (2021). doi: https://doi.org/10.1093/eurheartj/ehab703
Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S, Gonzalo N, Jan van Geuns R, Onuma Y, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Piek JJ, Appleby C, Fath-Ordoubadi F, Zaman A, Van Mieghem NM, Uren N, Zueco J, Buszman P, Iniguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, de Vries T, Taggart D, Farooq V, Spitzer E, Tijssen J, Escaned J. Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study. Eur Heart J. 2021 Oct 07; doi: 10.1093/eurheartj/ehab703. Epub 2021 Oct 07. PMID: 34617993.
Copy Download .nbib Format: NLM
ERS clinical practice guidelines on treatment of sarcoidosis.

The European respiratory journal

Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR.
PMID: 34140301
Eur Respir J. 2021 Dec 16;58(6). doi: 10.1183/13993003.04079-2020. Print 2021 Dec.

BACKGROUND: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain,...

Cite
Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6)doi: 10.1183/13993003.04079-2020.
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., Israel-Biet, D., Grutters, J. C., Drent, M., Culver, D. A., Bonella, F., Antoniou, K., Martone, F., Quadder, B., Spitzer, G., Nagavci, B., Tonia, T., Rigau, D., & Ouellette, D. R. (2021). ERS clinical practice guidelines on treatment of sarcoidosis. The European respiratory journal, 58(6), . https://doi.org/10.1183/13993003.04079-2020
Baughman, Robert P, et al. "ERS clinical practice guidelines on treatment of sarcoidosis." The European respiratory journal vol. 58,6 (2021). doi: https://doi.org/10.1183/13993003.04079-2020
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec 16;58(6). doi: 10.1183/13993003.04079-2020. Print 2021 Dec. PMID: 34140301.
Copy Download .nbib Format: NLM
Showing 349 to 357 of 357 entries